Retapamulin
(Synonyms: 瑞他帕林; SB-275833) 目录号 : GC13370
A bacterial protein synthesis inhibitor
Cas No.:224452-66-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Retapamulin is a pleuromutilin antibiotic [1].
Retapamulin is developed for topical treatment of skin infections which is mainly caused by gram-positive organisms, β-hemolytic streptococci and coagulase-negative staphylococci. Retapamulin is especially used against those drug resistance strains. In the in vitro studies, retapamulin demonstrates potent activity and a broad spectrum. It shows excellent antimicrobial activities against S. aureus, S. epidermidis, S. saprophyticus, S. pyogenes, S. agalactiae and Viridans group streptococci with MIC50 values of 0.06μg/ml, 0.06μg/ml, 0.12μg/ml, 0.008μg/ml, 0.016μg/ml and 0.03μg/ml, respectively. Retapamulin plays its antibiotic role through binding to a unique site of the bacterial ribosome [1, 2].
References:
[1] Jones R N, Fritsche T R, Sader H S, et al. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrobial agents and chemotherapy, 2006, 50(7): 2583-2586.
[2] Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrobial agents and chemotherapy, 2006, 50(11): 3882-3885.
| Cas No. | 224452-66-8 | SDF | |
| 别名 | 瑞他帕林; SB-275833 | ||
| 化学名 | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(((1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)thio)acetate | ||
| Canonical SMILES | O[C@H]([C@](C)(C=C)C1)[C@H](C)[C@]2(CCC3=O)[C@]3([H])[C@@]([C@@H]1OC(CSC4C[C@](CC5)([H])N(C)[C@]5([H])C4)=O)(C)[C@H](C)CC2 | ||
| 分子式 | C30H47NO4S | 分子量 | 517.76 |
| 溶解度 | ≥ 16.15mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9314 mL | 9.657 mL | 19.314 mL |
| 5 mM | 0.3863 mL | 1.9314 mL | 3.8628 mL |
| 10 mM | 0.1931 mL | 0.9657 mL | 1.9314 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。